2024-10-31 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance vs. S&P 500 (VOO)**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. The company has a long history of stability and consistent performance. 

* **Cumulative Return (JNJ):** 33.61%
* **Cumulative Return (VOO):** 136.74%
* **Lag:** -103.13%
* **Relative Lag:** 2.22%

This indicates that JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative lag suggests that this underperformance is within the lower end of the historical range.

**2. Recent Price Movement:**

* **Last Market:** 160.63
* **5-Day Moving Average:** 162.42
* **20-Day Moving Average:** 162.09
* **60-Day Moving Average:** 162.67

The price is currently below all three moving averages, suggesting potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 48.38
* **PPO:** -0.14
* **Delta_Previous_Relative_Divergence:** -5.73 (Short-term downtrend)
* **Expected Return:** 0.0% (Long-term potential for outperformance over S&P 500)

The RSI and PPO indicate a neutral to slightly bearish market sentiment. The negative divergence in the Relative Divergence indicator suggests a short-term downtrend. However, the expected return remains neutral, implying a potential for long-term outperformance over the S&P 500 with a long-term investment strategy.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue    |
|------------|----------|------------|
| 2024-10-23 | 1.12     | $22.47 B$ |
| 2024-07-25 | 1.95     | $22.45 B$ |
| 2024-05-01 | 1.35     | $21.38 B$ |
| 2024-02-16 | 1.68     | $21.39 B$ |
| 2023-10-27 | 10.32    | $21.35 B$ |

The latest earnings were released on 2024-10-23, with EPS of $1.12 and revenue of $22.47 B$. The EPS came in lower than expected.  

**5. Financial Information:**

**1) Revenue and Profitability**

| Quarter     | Revenue  | Profit Margin |
|-------------|----------|--------------|
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |
| 2023-09-30 | $21.35B | 69.06%       |

**2) Capital and Profitability**

| Quarter     | Equity     | ROE       |
|-------------|------------|------------|
| 2024-09-30 | $70.16B  | 3.84%     |
| 2024-06-30 | $71.54B  | 6.55%     |
| 2024-03-31 | $70.02B  | 4.65%     |
| 2023-12-31 | $68.77B  | 5.89%     |
| 2023-09-30 | $71.23B  | 36.54%    |

JNJ continues to demonstrate consistent revenue and profitability, with strong profit margins and healthy equity. The company's ROE fluctuates, indicating varying levels of efficiency in using its shareholder's equity to generate profits. 

**6. News and Recent Issues:**

* **Recent Earnings:** JNJ's recent earnings release on October 23, 2024, fell short of analyst expectations. 
* **Market Outlook:** Despite recent underperformance, JNJ remains a stable company with a solid history of dividend payments.
* **Analyst Opinions:**  Analysts generally remain optimistic about JNJ's long-term prospects, citing the company's strong brand, diverse product portfolio, and consistent dividend payments.

**7. Overall Analysis:**

JNJ remains a defensive stock with a long history of stability and dividend payments. However, the company's recent underperformance against the broader market, coupled with the recent earnings miss, suggests potential for continued volatility in the short term. Nonetheless, JNJ remains a promising long-term investment with a solid track record of profitability and strong fundamentals. The company's continued focus on innovation and expansion in its core businesses, particularly in pharmaceuticals and medical devices, suggests potential for future growth. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice.  
